<DOC>
	<DOCNO>NCT00024154</DOCNO>
	<brief_summary>This phase II trial study well give trastuzumab together gefitinib work treat patient HER2-positive breast cancer . The monoclonal antibody trastuzumab locate breast cancer cell HER2 surface either kill deliver tumor-killing substance without harm normal cell . Biological therapy gefitinib may also interfere growth tumor cell may enhance effect trastuzumab . Combining trastuzumab gefitinib may effective treatment metastatic breast cancer high amount HER2</brief_summary>
	<brief_title>Trastuzumab Gefitinib Treating Patients With Metastatic Breast Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . Determine response rate , duration response , time progression patient metastatic breast cancer overexpresses HER2-neu treated trastuzumab ( Herceptin ) gefitinib . II . Determine phase II dose gefitinib give combination trastuzumab patient . III . Determine toxicity regimen patient . IV . Determine 3- 6-month progression-free survival patient treat regimen . V. Correlate response rate plasma level circulate HER2 tumor level epidermal growth factor receptor , activate HER2 , HER2 receptor , measure immunohistochemistry and/or fluorescent situ hybridization ( FISH ) , patient treat regimen . OUTLINE : This multicenter , dose-escalation study gefitinib . The phase I portion study open 5 ECOG institution . The phase I portion complete , study open ECOG-affiliated institution . Phase I ( complete ) : Patients receive trastuzumab ( Herceptin ) IV 30-90 minute weekly oral gefitinib daily begin day 1 . Cohorts 3-6 patient receive escalate dos gefitinib maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose-limiting toxicity . Once MTD establish , additional patient accrue phase II portion study treat dose . Phase II : Patients receive oral gefitinib daily ( MTD establish phase I ) trastuzumab IV weekly week 24 , time trastuzumab give every 3 week ( daily gefitinib ) disease progression unacceptable toxicity . After completion study treatment , patient follow every 3 month 2 year study entry .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms , Male</mesh_term>
	<mesh_term>Gefitinib</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histologically confirm metastatic adenocarcinoma breast Patients may standard firstline chemotherapy treatment metastatic disease Overexpression HER2neu ( HER2 3+ immunohistochemistry gene amplification measure fluorescent situ hybridization ) Measurable disease Patients prior adjuvant chemotherapy may fail fail firstline chemotherapy metastatic disease No 2 prior systemic chemotherapy regimens metastatic disease Relapse receiving within 6 month completion adjuvant chemotherapy consider failure 1 regimen metastatic disease No untreated brain metastasis brain metastasis undergoing radiotherapy Previously treat brain metastasis respond radiotherapy and/or surgery allow sole site measurable disease Hormone receptor status : Not specify Male female Performance status ECOG 02 Granulocyte count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin great 1.5 time upper limit normal ( ULN ) AST ALT great 3 time ULN ( 5 time ULN liver metastasis present ) INR great 1.5 time ULN PT PTT great 1.5 time ULN Creatinine great 1.5 mg/dL No trace blood protein urine LVEF â‰¥ 50 % MUGA scan No prior New York Heart Association class IIV heart disease No PR prolongation atrioventricular block ECG Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception ( preferably nonhormonal ) Random blood sugar le 2.5 time ULN No malignancy within past 5 year except curatively treat basal cell squamous cell skin cancer carcinoma situ cervix No acute chronic medical psychiatric condition laboratory abnormality would preclude study participation No prior trastuzumab ( Herceptin ) No concurrent immunologic therapy See Disease Characteristics Recovered prior cytotoxic chemotherapy No prior cumulative dose doxorubicin 360 mg/m^2 No concurrent chemotherapy At least 2 week since prior hormonal therapy No concurrent hormonal therapy , include tamoxifen No concurrent dexamethasone , progesterone , glucocorticoid See Disease Characteristics At least 2 week since prior radiotherapy No prior radiotherapy target lesion site measurable disease No concurrent radiotherapy See Disease Characteristics No prior organ allograft No prior gefitinib No prior immunosuppressive therapy At least 2 week since prior cytotoxic drug No concurrent carbamazepine , ethosuximide , griseofulvin , nafcillin , nelfinavir mesylate , nevirapine , oxcarbazepine , phenobarbital , phenylbutazone , phenytoin , primidone , rifabutin , rifampin , rofecoxib , Hypericum perforatum ( St. John 's Wort ) , sulfadimidine , sulfinpyrazone , troglitazone , grapefruit juice No concurrent investigational agent No concurrent topical eye agent Concurrent bisphosphonates allow hypercalcemia and/or prophylaxis bone metastasis</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2013</verification_date>
</DOC>